产品详情
特异性(Specificity)
Specifically recognizes MMAF and does not recognize MMAE.
抗体来源(Source)
Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
克隆号(Clone)
1M1E12
亚型(Isotype)
Rabbit IgG | Rabbit Kappa
偶联(Conjugate)
Unconjugated
免疫原(Immunogen)
MMAF-BSA.
应用(Application)
ApplicationRecommended UsageELISA0.06-125 ng/mL纯化(Purification)
Protein A purified / Protein G purified
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
质量管理控制体系(QMS)
数据展示
活性(Bioactivity)-ELISA
Immobilized IgG1-MMAF at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214) with a linear range of 0.06-2 ng/mL (QC tested).
ProtocolSerial dilutions of MMAF were added into Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214): IgG1-MMAF binding reactions. The half maximal inhibitory concentration (IC50) is 0.1106 μg/mL (Routinely tested).
Protocol
交叉验证-Cross Verification
ELISA binding of Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214) with Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conju-gated antibody respectively.
The coating antibody was Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214), used at 1 μg/mL concentration. The primary an-tibody were different payload conjugated antibodies, including Doxorubicin-ADC, Disitamab Vedotin (RC48), IgG1-MMAF, Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 conjugated antibodies used at 0.25 μg/mL con-centration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Anti-body (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-MMAF specific Antibody, Rabbit IgG (1M1E12) (Cat. No. MMF-MY2214) is specific to IgG1-MMAF and has no cross-reactivity with Doxorubi-cin-ADC, Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).
用户评价 发表评论
